Pfizer and BioNTech’s COVID-19 Vaccine Booster Receive the US FDA’s EUA for the Treatment of COVID-19

 Pfizer and BioNTech’s COVID-19 Vaccine Booster Receive the US FDA’s EUA for the Treatment of COVID-19

Shots:

  • The US FDA has issued a EUA for the COVID-19 booster vaccine (administered at least 6mos. after completion of primary 2 doses) to prevent COVID-19 in individuals aged ≥65yrs. & 18 through 64yrs. of age who at high risk of severe COVID-19
  • The EUA is based on clinical data that showed higher neutralizing Ab titers against COVID-19 & other variants compared with the levels observed after 2 doses, frequency of reactions was similar or lower than after dose two & AEs was consistent with other clinical safety data
  • Previously, a third dose of the vaccine was authorized for individuals aged 12yrs. who have undergone a solid organ transplant or diagnosed with other conditions

Click here to­ read full press release/ article | Ref: Pfizer | Image: Wall Street Journal